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Summary
Background: Tuberculosis (TB) has emerged as a serious public health problem in the country of
Georgia. However, little or no data exist on rates and risk factors for drug-resistant TB, including
multidrug-resistant (MDR)-TB, in Georgia.
Objective: To assess the prevalence and risk factors for drug-resistant TB.
Methods: A cross-sectional prospective survey of patients with suspected pulmonary TB was
carried out at four sentinel sites (Tbilisi, Zugdidi, Kutaisi, and Batumi) in Georgia between
January 1, 2001 and December 31, 2004.
Results: Among 1422 patients with suspected pulmonary TB, 996 (70.0%) were culture positive;
931/996 (93.5%) had drug susceptibility testing performed. Overall, 64.0% of patients (48.3% of
new and 85.3% of retreatment cases) had positive cultures for Mycobacterium tuberculosis
resistant to 1 first-line antituberculosis drugs. The overall prevalence of MDR-TB was 28.1%
(10.5% of newly diagnosed patients and 53.1% of retreatment cases). In multivariate analysis, risk
factors for MDR-TB included: being a retreatment case (prevalence ratio (PR) = 5.28, 95% CI 3.95—
7.07), history of injection drug use (PR = 1.59, 95% CI 1.21—2.09), and female gender (PR = 1.36,
95% CI 1.12—1.65).
Conclusions: MDR-TB has emerged as a serious public health problem in Georgia and will greatly
impact TB control strategies.
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Tuberculosis (TB) has emerged as an enormous public health
problem in the former Soviet republics, due to economic
decline and the general failure of tuberculosis control and
other health services following the break-up of the Soviet
Union.1,2 The country of Georgia, an independent nation that
was previously part of the former Soviet Union (Figure 1), has
one of the highest rates of tuberculosis among former Soviet
republics.3,4 In 2005, a total of 6448 TB cases were reported
in Georgia; the incidence of TB was 97 cases per 100 000
population and the prevalence 147 cases per 100 000 popula-
tion.5 In 2003, the cohort treatment success rate was 67%; an
additional 2% died, 4% failed, 15% defaulted, 8% transferred,
and 4% had missing data.3 The situation in Georgia was
exacerbated by a civil war in 1992—1993 following indepen-
dence, which resulted in several hundred thousand internally
displaced persons who have been noted to have high rates of
tuberculosis.1
Despite high rates of TB in Georgia, little or no data exist
on the prevalence of or risk factors for drug-resistant tuber-
culosis. High rates of drug-resistant TB were reported among
persons incarcerated in Georgian prisons in the late 1990s,6
but there are little or no previous data available about rates
or risk factors for drug-resistant tuberculosis or multidrug-
resistant (MDR) tuberculosis (defined as resistance to at least
isoniazid and rifampin) among the Georgian civilian popula-
tion. Drug-resistant TB, especially MDR-TB, is associated with
significantly higher morbidity and mortality than the drug-
susceptible disease.7—9 Drug resistance rates also reflect
current and prior effectiveness of TB control programs.10
Drug-resistant TB may threaten TB control efforts by redu-
cing the effectiveness of short-course antituberculosis regi-
mens delivered under the World Health Organization (WHO)
recommended directly observed therapy, short course
(DOTS) strategy7,11 and by disproportionately absorbing TB
control program resources.Figure 1 Map of the country of Georgia. Red dots show the four
Kutaisi, and Batumi).The purpose of our prospective study was to assess rates of
and risk factors for drug-resistant TB, including MDR-TB, in
Georgia. This information is important for developing effec-
tive TB control strategies in Georgia and assessing the need
for implementation of the DOTS-Plus strategy for the treat-
ment of MDR-TB.12
Methods
Study population
A cross-sectional prospective survey was carried out at four
sentinel sites in Georgia. Patients aged 15 years and older,
highly suspected of having pulmonary tuberculosis (i.e.,
patients with clinical symptoms and chest radiograph findings
suggestive of TB), presenting to four sentinel sites (inpatient
facilities in four Georgian cities — Tbilisi, Zugdidi, Kutaisi,
and Batumi) between January 1, 2001 and December 31, 2004
in the country of Georgia were eligible for enrollment into
the study. In Georgia, patients are offered hospitalization for
the intensive phase of TB treatment. Written informed con-
sent was obtained from all patients prior to enrollment. The
study was approved by the Georgian National Center for
Tuberculosis and Lung Disease (NCTLD) Ethics Committee,
the Georgian National Center for Disease Control Ethics
Committee, and the Emory University Institutional Review
Board (IRB).
Data collection and definitions
Clinical, demographic, and epidemiologic data were col-
lected through interview of patients and review of medical
records. Demographic data included patient age, gender,
nationality (Georgian, Armenian, Azeri, Russian, and other),
region of residence, status of an internally displaced person
(IDP), incarceration history, employment status, and historysentinel sites where the study was conducted (Tbilisi, Zugdidi,
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on comorbid illnesses including hepatitis, HIV infection,
diabetes mellitus, gastritis, and peptic ulcer disease were
collected. The case status for each patient with TB was
recorded (newly diagnosed vs. previously treated) as well
as the primary reason for culture examination (initial diag-
nosis vs. follow-up visit). The study focused primarily on
patients with TB who had positive cultures.
New cases were defined as patients who had never had
treatment for TB or who had received antituberculosis
drugs for less than one month. Retreatment cases were
defined as patients who had a prior history of treatment
with antituberculosis drugs for more than one month.13
Retreatment cases included relapses, treatment after fail-
ure, treatment after default, and chronic cases (i.e., a
patient with TB who is sputum-positive at the end of a
standard retreatment regimen). Multidrug-resistance
(MDR) was defined as resistance to at least both isoniazid
and rifampin.14 Monoresistance was defined as resistance
exclusively to one of the four first-line antituberculosis
drugs tested.14 Polyresistance was defined as resistance
to two or more of the five first-line antituberculosis drugs,
but not both isoniazid and rifampin.
Laboratory methods
Three sputum samples for acid-fast bacillus (AFB) smear
microscopy and culture were obtained from each patient
enrolled into the study. Specimens were obtained at each
sentinel site and then transported to the Georgian National
Reference Laboratory in Tbilisi where AFB cultures were
performed with Lowenstein—Jensen media using standard
methodologies.15 Drug susceptibility testing (DST) to first-
line antituberculosis drugs (isoniazid, rifampin, ethambu-
tol, and streptomycin) was performed on Mycobacterium
tuberculosis isolates using the absolute concentration
method.16 The concentrations of the antituberculosis drugs
tested were as follows: isoniazid 0.1 mg/ml, rifampin
40.0 mg/ml, streptomycin 10.0 mg/ml, and ethambutol
2.0 mg/ml.
Statistical analysis
All statistical analyses were performed using SAS, version 9.0
(SAS Institute Inc., Cary, NC, USA). Trends in the prevalence
of drug resistance over time were assessed using the Chi-
square test for trends. Risk factors for having any resistance
and multidrug-resistance among culture-confirmed TB cases
were assessed. Univariate analysis was performed to deter-
mine unadjusted association of TB drug resistance with
patient clinical and demographic characteristics. For dichot-
omous variables, prevalence ratios (PR) with 95% confidence
intervals (CI) were calculated using PROC GENMOD in SAS. To
obtain the adjusted estimates, two multivariate log-binomial
regressionmodels were fittedwith DSTresults (any resistance
vs. fully susceptible and MDR-TB vs. non-MDR-TB, respec-
tively) as outcome variables. Variables significantly asso-
ciated with an outcome of interest in the univariate
analysis as well as potential confounders and effect-modifiers
based on literature review were included in the final multi-
variate model. Interaction and confounding were assessed. A
p-value of 0.05 was considered statistically significant.Results
A total of 2212 patients underwent culture examination
during the four-year period. Patients with tuberculosis who
had sputum collected at these sites for reasons other than
diagnosis of TB (N = 607; e.g., follow-up specimens for
patients undergoing current treatment or unknown reason
for sputum examination) were excluded from the analysis. A
total of 1605 patients with suspected tuberculosis who had
sputum specimens collected for diagnostic purposes as the
primary reason for culture examination at four sentinel sites
in Georgia were enrolled into the study. Among the 1605
patients with suspected TB enrolled into the study, 1422
(88.6%) had valid culture results (either positive or negative
cultures) and constituted the sample for culture confirmation
analysis (Figure 2). Of these 1422 patients, 996 (70.0%) had a
positive culture for M. tuberculosis. Drug susceptibility test-
ing results were available for 931 of 996 patients (93.5%) with
positive cultures. AFB smear results were available for 1188
patients with positive or negative culture results; of these
925 (77.9%) were AFB smear positive and 263 (22.1%) were
smear negative. A total of 66 patients with a negative smear
(5.6% of all with available smear results) had a positive
culture.
Themean age of the 1422 patients with culture results was
38 years (range 15—81 years); 73.5% were male, 87.1% had
Georgian nationality, and 54.3% resided in Tbilisi (Table 1).
The history of previous treatment was known for 1154 of 1422
patients (81.2%), and of those, 682 (59.1%) were newly
diagnosed cases and 472 (40.9%) were retreatment cases
(Table 1). Having a positive culture for M. tuberculosis was
significantly associated with male gender and residence out-
side Tbilisi (Table 1). Patients in age groups 55—64 and >65
years were significantly less likely to have had a positive
culture compared to those aged 15—24 years. Patients with
unknown treatment history had positive cultures significantly
less often than new cases.
Risk of drug-resistant tuberculosis
Drug susceptibility test (DST) results were available on M.
tuberculosis isolates recovered from 931 patients (534
newly diagnosed cases, 388 retreatment cases, and nine
cases with unknown treatment history). The prevalence of
different patterns of resistance is shown in Table 2. Over-
all, 596 patients (64.0%; 258 (48.3%) new and 331 (85.3%)
retreatment cases) had isolates resistant to one or more
first-line antituberculosis drugs. Risk factors for resistance
to one or more antituberculosis drugs in univariate analysis
are shown in Table 3. When nine patients with unknown
treatment history were excluded, analysis yielded similar
results (data not shown). In multivariate analysis,
having any resistance to one or more first-line antituber-
culosis drugs was independently associated with being a
retreatment case (PR = 1.75, 95% CI 1.58—1.94) and being
an internally displaced person (PR = 1.10, 95% CI 1.00—
1.21).
Two hundred sixty-two of 931 patients (28.1%) were
demonstrated to have MDR-TB. The prevalence of MDR-TB
was significantly higher among retreatment cases than
among newly diagnosed cases (206/388 (53.1%) vs. 56/534
Figure 2 Study sample of patients with suspected pulmonary tuberculosis at four sentinel sites in the country of Georgia (DST = drug
susceptibility testing; TB = tuberculosis).
Table 1 Demographic characteristics of suspected pulmonary tuberculosis cases at four sentinel sites in Georgia, 2001—2004
Variable All suspected TB cases (N = 1422) Culture positive (N = 996) Culture negative (N = 426) PRa (95% CI)
Age group (years)
15—24 237 (16.7%) 174 (17.5%) 63 (14.8%) Ref.
25—34 408 (28.7%) 301 (30.2%) 107 (25.1%) 1.00 (0.91—1.11)
35—44 376 (26.4%) 285 (28.6%) 91 (21.4%) 1.03 (0.94—1.14)
45—54 216 (15.2%) 146 (14.7%) 70 (16.4%) 0.92 (0.82—1.04)
55—64 111 (7.8%) 65 (6.5%) 46 (10.8%) 0.80 (0.67—0.95)
>65 74 (5.2%) 25 (2.5%) 49 (11.5%) 0.46 (0.33—0.64)
Gender
Male 1045 (73.5%) 749 (75.2%) 296 (69.5%) 1.09 (1.01—1.19)
Female 377 (26.5%) 247 (24.8%) 130 (30.5%) Ref.
Case status
New 682 (48.0%) 579 (58.1%) 103 (24.2%) Ref.
Retreatment 472 (33.2%) 408 (41.0%) 64 (15.0%) 0.98 (0.94—1.03)
Unknown 268 (18.8) 9 (0.9) 259 (60.8) 0.04 (0.02—0.07)
Residence (994b/417c)
Tbilisi 766 (54.3%) 513 (51.6%) 253 (60.7%) 0.88 (0.84—0.96)
Other 645 (45.7%) 481 (48.4%) 164 (39.3%) Ref.
Nationality
Georgian 1239 (87.1%) 872 (87.6%) 367 (86.2%) 1.04 (0.93—1.16)
Other 183 (12.9%) 124 (12.4%) 59 (13.8%) Ref.
a Unadjusted prevalence ratio (PR) for comparison of culture positive to culture negative patients.
b Number of patients with positive cultures for whom data were available.
c Number of patients with negative cultures for whom data were available.
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Table 2 Prevalence of first-line antituberculosis drug resistance at four sentinel sites in Georgia, 2001—2004
Resistance profile All cases New cases Retreatment
cases
Unknown
treatment
history
n % n % n % n %
Total number of strains tested 931 100.0 534 100.0 388 100.0 9 100.0
I. Any drug resistancea 596 64.0 258 48.3 331 85.3 7 77.8
INH 442 47.5 159 29.8 280 72.2 3 33.3
RIF 287 30.8 66 12.4 220 56.7 1 11.1
SM 490 52.6 199 37.3 284 73.2 7 77.8
EMB 210 22.7 56 10.5 154 39.7 0 0
II. Monoresistanceb 188 20.2 126 23.6 59 15.2 3 33.3
INH only 59 6.3 39 7.3 20 5.2 0 0
RIF only 7 0.8 3 0.6 4 1.0 0 0
SM only 108 11.6 75 14.0 30 7.7 3 33.3
EMB only 14 1.5 9 1.7 5 1.3 0 0
III. MDR-TBa 262 28.1 56 10.5 206 53.1 0 0
INH + RIF 15 1.6 6 1.1 9 2.3 0 0
INH + RIF + EMB 6 0.6 0 0 6 1.6 0 0
INH + RIF + SM 98 10.5 26 4.9 72 18.5 0 0
INH + RIF + SM + EMB 143 15.4 24 4.5 119 30.7 0 0
IV. Polyresistancec 146 15.7 76 14.2 66 17.0 4 44.4
INH + EMB 2 0.2 1 0.2 1 0.3 0 0
INH + SM 86 9.2 48 9.0 35 9.0 3 33.3
INH + EMB + SM 33 3.5 15 2.8 18 4.6 0 0
RIF + EMB 3 0.3 1 0.2 2 0.5 0 0
RIF + SM 13 1.4 5 0.9 7 1.8 1 11.1
RIF + EMB + SM 2 0.2 1 0.2 1 0.3 0 0
EMB + SM 7 0.8 5 0.9 2 0.5 0 0
Number of drugs resistant to:
Susceptible to 4 drugs 335 36.0 276 51.7 57 14.7 2 22.2
Resistant to 1 drug 188 20.2 126 23.6 59 15.2 3 33.3
Resistant to 2 drugs 126 13.5 66 12.3 56 14.4 4 44.4
Resistant to 3 drugs 139 14.9 42 7.9 97 25.0 0 0
Resistant to 4 drugs 143 15.4 24 4.5 119 30.7 0 0
INH, isoniazid; RIF, rifampin; EMB, ethambutol; SM, streptomycin; MDR-TB, multidrug-resistant tuberculosis (resistance to at least both
isoniazid and rifampin); polyresistance, resistance to two or more drugs but not both isoniazid and rifampin.
a p < 0.001 in Chi-square test for comparison of prevalence of resistance pattern in retreatment cases to that in new cases.
b p = 0.002 in Chi-square test for comparison of prevalence of resistance pattern in retreatment cases to that in new cases.
c p = 0.25 in Chi-square test for comparison of prevalence of resistance pattern in retreatment cases to that in new cases.
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cases (143/262 (54.6%)) were resistant to all four first-line
antituberculosis drugs tested (Table 2). Retreatment cases
were significantly more likely to have MDR-TB than non-
MDR-TB (206/262 patients (78.6%) with MDR-TB were
retreatment cases compared to 182/669 (27.2%) non-
MDR-TB cases (PR = 5.06, 95% CI 3.88—6.60) (Table 4)).
Other significant predictors of MDR-TB in univariate ana-
lysis included patient age groups 25—34 and 35—44 years
(compared to age group 15—24 years), living outside of
Tbilisi, history of incarceration, unemployment, and his-
tory of injection drug use (Table 4). When nine patients
with unknown treatment history were excluded from ana-
lysis, the results were similar (data not shown). In multi-
variate analysis, independent risk factors for MDR-TB
included being a retreatment case (PR = 5.28, 95% CI3.95—7.07), history of injection drug use (PR = 1.59, 95%
CI 1.21—2.09), and female gender (PR = 1.36, 95% CI 1.12—
1.65) (Table 5).
Resistance to rifampin was a significant predictor of resis-
tance to isoniazid and streptomycin: 262 of 287 isolates
(91.3%) resistant to rifampin were also resistant to isoniazid
(PR = 11.59, 95% CI 7.85—17.12), and 256 isolates (89.2%)
were also resistant to streptomycin (PR = 7.43, 95% CI 5.24—
10.55).
The prevalence of any drug resistance among TB cases
significantly decreased during the study period from 83.5% in
2001 to 54.1% in 2004 ( p-value for trend <0.001) (Figure 3).
The prevalence of MDR-TB decreased from 33.3% in 2001 to
20.0% in 2004 ( p-value for trend <0.001) (Figure 3). Similar
trends were observed for both new and retreatment cases
(data not shown).
Table 3 Univariate analysis of association of having resistance to at least one first-line antituberculosis drug with patient
demographic and clinical characteristics (N = 931)
Variable Any drug resistance (N = 596) Drug susceptible (N = 335) Prevalence ratio (PR) (95% CI)
n (%) n (%)
Age group (years)
15—24 83 (13.9) 78 (23.3) Ref.
25—34 197 (33.0) 84 (25.1) 1.36 (1.15—1.61)
35—44 187 (31.4) 87 (25.9) 1.32 (1.12—1.57)
45—54 76 (12.8) 58 (17.3) 1.10 (0.89—1.36)
55—64 41 (6.9) 16 (4.8) 1.40 (1.12—1.74)
>65 12 (2.0) 12 (3.6) 0.97 (0.63—1.49)
Gender
Female 147 (24.7) 81 (24.2) 1.01 (0.90—1.13)
Male 449 (75.3) 254 (75.8) Ref.
Case status
New 258 (43.3) 276 (82.4) Ref.
Retreatment 331 (55.5) 57 (17.0) 1.77 (1.60—1.95)
Unknown 7 (1.2) 2 (0.6) 1.61 (1.12—2.31)
Residence (595a/334b)
Tbilisi 285 (47.9) 193 (57.8) 0.87 (0.79—0.96)
Other 310 (52.1) 141 (42.2) Ref.
Nationality
Georgian 510 (85.6) 305 (91.0) 0.84 (0.75—0.95)
Other 86 (14.4) 30 (9.0) Ref.
Internally displaced person (537a/284b)
Yes 37 (6.9) 8 (2.8) 1.28 (1.10—1.48)
No 500 (93.1) 276 (97.2) Ref.
History of incarceration (537a/283b)
Yes 87 (16.2) 16 (5.7) 1.35 (1.22—1.49)
No 450 (83.8) 267 (94.3) Ref.
Unemployed (509a/271b)
Yes 427 (83.9) 206 (76.0) 1.21 (1.04—1.41)
No 82 (16.1) 65 (24.0) Ref.
Tobacco use (538a/284b)
Yes 268 (49.8) 141 (49.6) 1.00 (0.91—1.11)
No 270 (50.2) 143 (50.4) Ref.
Alcohol use (537a/283b)
Yes 145 (27.0) 76 (26.9) 1.00 (0.90—1.12)
No 392 (73.0) 207 (73.1) Ref.
History of injection drug use (477a/272b)
Yes 19 (4.0) 3 (1.1) 1.37 (1.15—1.63)
No 458 (96.0) 269 (98.9) Ref.
Hepatitis (508a/271b)
Yes 40 (7.9) 14 (5.2) 1.15 (0.97—1.36)
No 468 (92.1) 257 (94.8) Ref.
HIV
Yes 5 (0.8) 0 (0) Undefined
No 135 (22.7) 92 (27.5) Ref.
Unknown 456 (76.5) 243 (72.5) 1.06 (0.97—1.17)
Diabetes mellitus (518a/273b)
Yes 25 (4.8) 11 (4.0) 1.06 (0.88—1.33)
No 493 (95.2) 262 (96.0) Ref.
History of gastritis/peptic ulcer disease (517a/273b)
Yes 17 (3.3) 11 (4.0) 0.93 (0.68—1.25)
No 500 (96.7) 262 (96.0) Ref.
a Number of patients with any drug resistance for whom data were available.
b Number of patients with drug susceptible cultures for whom data were available.
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Table 4 Univariate analysis of association of having MDR-TB and patient demographic and clinical characteristics (N = 931)
Variable MDR-TB case (N = 262) Non-MDR-TB case (N = 669) Prevalence ratios (PR) (95% CI)
n (%) n (%)
Age group, years
15—24 33 (12.6) 128 (19.1) Ref.
25—34 90 (34.4) 191 (28.6) 1.56 (1.10—2.21)
35—44 83 (31.7) 191 (28.6) 1.48 (1.04—2.10)
45—54 36 (13.7) 98 (14.6) 1.31 (0.87—1.98)
55—64 15 (5.7) 42 (6.3) 1.28 (0.76—2.18)
>65 5 (1.9) 19 (2.8) 1.02 (0.44—2.35)
Gender
Female 70 (26.7) 158 (23.6) 1.12 (0.89—1.41)
Male 192 (73.3) 511 (76.4) Ref.
Case status by history of TB treatment
New 56 (21.4) 478 (71.4) Ref.
Retreatment 206 (78.6) 182 (27.2) 5.06 (3.88—6.60)
Unknown 0 (0) 9 (1.4) Undefined
Residence (261a/668b)
Tbilisi 110 (42.1) 368 (55.1) 0.69 (0.56—0.85)
Other 151 (57.9) 300 (44.9) Ref.
Nationality
Georgian 235 (89.7) 580 (86.7) 1.24 (0.88—1.75)
Other 27 (10.3) 89 (13.3) Ref.
Internally displaced person (246a/575b)
Yes 17 (6.9) 28 (4.9) 1.28 (0.87—1.89)
No 229 (93.1) 547 (95.1) Ref.
History of incarceration (246a/574b)
Yes 53 (21.5) 50 (8.7) 1.91 (1.53—2.39)
No 193 (78.5) 524 (91.3) Ref.
Unemployed (235a/545b)
Yes 203 (86.4) 430 (78.9) 1.47 (1.06—2.04)
No 32 (13.6) 115 (21.1) Ref.
Tobacco use (247a/575b)
Yes 122 (49.4) 287 (49.9) 0.99 (0.80—1.21)
No 125 (50.6) 288 (50.1) Ref.
Alcohol use (246a/574b)
Yes 65 (26.4) 156 (27.2) 0.97 (0.77—1.23)
No 181 (73.6) 418 (72.8) Ref.
History of injection drug use (216a/533b)
Yes 15 (6.9) 7 (1.3) 2.47 (1.81—3.36)
No 201 (93.1) 526 (98.7) Ref.
History of hepatitis (237a/542b)
Yes 20 (8.4) 34 (6.3) 1.24 (0.86—1.78)
No 217 (91.6) 508 (93.7) Ref.
HIV
Yes 2 (0.8) 3 (0.5) 1.40 (0.47—4.17)
No 65 (24.8) 162 (24.2) Ref.
Unknown 195 (74.4) 504 (75.3) 0.97 (0.77—1.24)
Diabetes (243a/548b)
Yes 13 (5.3) 23 (4.2) 1.19 (0.76—1.85)
No 230 (94.7) 525 (95.8) Ref.
History of gastritis/peptic ulcer disease (243a/547b)
Yes 11 (4.5) 17 (3.1) 1.29 (0.80—2.07)
No 232 (95.5) 530 (96.9) Ref.
a Number of patients with positive cultures for whom data were available.
b Number of patients with negative cultures for whom data were available.
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Table 5 Multivariate analysis of risk factors for multidrug-resistant tuberculosis (MDR-TB) in Georgia
Variable Adjusted prevalence ratios (PR) (95% CI) p-Value
Retreatment case 5.28 (3.95—7.07) <0.001
History of injection drug use 1.59 (1.21—2.09) <0.001
Female gender 1.36 (1.12—1.65) 0.002
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Our study demonstrated high rates of drug resistance includ-
ing MDR-TB in Georgia, among both newly diagnosed and
retreatment cases in the civilian population. Overall, 64.0%
of the TB cases had resistance to 1 antituberculosis drug
(48.3% of new and 85.3% of retreatment cases). The overall
prevalence of MDR-TB in Georgia in our study was 28.1%, with
very high prevalence both in newly diagnosed patients
(10.5%) and in retreatment cases (53.1%). Resistance to
any first-line drug was independently associated with being
a retreatment case and being an internally displaced person.
Independent risk factors for MDR-TB included being a retreat-
ment case, history of injection drug use, and female gender.
To our knowledge, our study is the first to report rates of
drug resistance among TB cases in a civilian population in
Georgia. High rates of MDR-TB (4—5% in new cases and 19—
25% in retreatment cases) have been reported from Abkha-
zia, an autonomous republic of Georgia, which functions
independently from Georgia.17,18 Our findings of high rates
of drug-resistant TB including MDR-TB in Georgia are similar
to what has been reported from other former Soviet repub-
lics. This region has among the highest prevalence of drug-
resistant TB in the world.19 In countries of the former Soviet
Union, MDR-TB rates have been reported to range from 4%
(Dashoguz, Turkmenistan) to 22.7% (Samara, Russia) in new
cases,20,21 and from 18% (Dashoguz, Turkmenistan) to 54—60%
(Republic of Lithuania and Arkhangelsk, Russia, respectively)
in retreatment cases.20,22,23 High rates of MDR-TB have also
been reported from Kazakhstan (14.2%), Tomsk, Russian
Federation (13.7%), and Estonia (12.2%).19 The median pre-
valence of resistance to the four first-line drugs amongFigure 3 Dynamics of the prevalence of antituberculosis drug
resistance over time in the country of Georgia, 2001—2004.retreatment cases in the countries of the former Soviet Union
was as high as 30%, compared to a median of 1.3% in all other
settings.19
In general, high rates of MDR-TB among newly diagnosed
patients suggest problems with TB control in the past, while
high rates of MDR-TB among retreatment cases is suggestive
of existing problems in the TB control program including
suboptimal treatment regimens and poor compliance with
treatment.10 TB has emerged as a major public health pro-
blem in Georgia following the dissolution of the Soviet Union
in 1991. Following independence, there was a civil war in
1992—1993, which resulted in a large number of internally
displaced persons. Living conditions in Georgia deteriorated
for a large proportion of the population, the healthcare
infrastructure was destroyed, and there was increased pov-
erty and migration. Inadequate management of TB services,
a significant shortage or absence of TB drugs, institutional
spread, and poor mechanisms to ensure adherence to treat-
ment1,2,6 are factors that have likely contributed to the high
rates of drug-resistant TB found in our study. High default
rates, which were reported to be as high as 23—25% among
new cases and 39% among retreatment cases in a study in
1995—1996, and 15% among new cases and 23% among
retreatment cases in 2003,2,3 have likely contributed to
the emergence of MDR-TB as well. While high rates of
drug-resistant TB including MDR-TB have been previously
reported from correctional facilities in Georgia,6 our study
is the first to report the prevalence and risk factors for drug-
resistant TB in the civilian population in Georgia.
The Georgian National Tuberculosis Program was estab-
lished in 1995. After its formation, Georgia started imple-
menting pilot projects based on the WHO-recommended
DOTS strategy with WHO support,2 and currently Georgia
has 100% of DOTS coverage.3 However, implementation of
DOTS in Georgia was limited until recent years, when robust
DOTS programs in selected regions (including Gori and Tbilisi)
were achieved. Temporal trends between 2001 and 2004 in
our study demonstrate a significant decrease in the overall
prevalence of MDR-TB, any resistance, and polyresistance
(resistance to two or more drugs but not both isoniazid and
rifampin) during the study period. These decreases likely
reflect enhanced TB control efforts in Georgia, including
implementation of standardized TB treatment (including
the provision of directly observed therapy), improved drug
supply system, improved diagnostics and laboratory capaci-
ties, implementation of proper recording and reporting, and
training of healthcare staff.2,24 Despite these improvements,
MDR-TB rates among new and retreatment cases remain high,
providing important challenges for TB control in Georgia. In
settings with existing high rates of MDR-TB, the current WHO
standard treatment policy of administration of first-line
drugs to retreatment cases should be revised.7 About one
third of the study population would not have responded to
High prevalence of MDR-TB in Georgia 643the standard WHO retreatment regimen with first-line drugs
(five drugs with the addition of streptomycin), and drug
resistance could be amplified by receiving such regimens.
Better access to DST results including rapid DST methods at
the time of TB diagnosis would facilitate appropriate selec-
tion of treatment regimens. Limited resources and laboratory
capacity remain limitations to the implementation of this
strategy. However, increasing laboratory capacity to deal
with MDR-TB as recommend by the Global Plan to Stop TB
(e.g., at a regional level) and better referral of specimens
from patients living in remote areas to regional/national
reference laboratories should be encouraged to meet this
challenge. The application of the Georgian National TB
Program to the Green Light Committee was approved, and
treatment of TB patients with drug-resistant tuberculosis
using second-line drugs started in 2007.
The strongest predictor of having both any drug resistance
and multidrug resistance in our study was being a retreat-
ment case. Previous treatment is a well-known risk factor for
the development of drug resistance.6,19,25 In a multivariate
analysis, the WHO/IUATLD (International Union Against
Tuberculosis and Lung Disease) Global Project on Anti-tuber-
culosis Drug Resistance Surveillance demonstrated that the
proportion of retreatment cases among the total number of
cases was significantly associated with both MDR and any drug
resistance.19 Previous treatment was also demonstrated as
the strongest determinant of MDR-TB in Europe in a systema-
tic review based on studies from 12 European countries.26
The likelihood of having MDR-TB increases linearly with
increasing total time of prior treatment.27 The current
WHO treatment recommendations for relapses and failures
in category II, which includes administration of five already
used drugs, may result in monotherapy and lead to further
amplification of resistance.7
In our study, internally displaced persons (IDP) had an
increased risk of having any resistance to first-line antitu-
berculosis drugs. IDPs are ethnic Georgians from the north-
west province of Abkhazia who were forced to flee their
homes during the civil war of 1992—1993 and reside in other
parts of Georgia, often in places such as former hotels or
hospitals where overcrowding is common. IDPs have been
reported to be at increased risk for TB infection and disease.1
These conditions may favor transmission of TB including drug-
resistant strains. Internally displaced status and risk of drug
resistance could be influenced by previous treatment. In
some studies, injection drug use has been reported to be a
risk factor for MDR-TB in newly diagnosed cases,21,28 while
other studies have failed to find such an association.29 The
association of injection drug use with MDR-TB could be
related to close contacts of drug users and transmission of
resistant stains within this group. Also it has been demon-
strated that injection drug use is a significant predictor of TB
treatment nonadherence,30 which may impact the develop-
ment of resistance.
Tuberculosis, including MDR-TB, is more common among
men. In a systematic review by Faustini et al.,26 MDR-TB cases
were more likely to be male in Western Europe, while in
Eastern Europemale gender was not associated with MDR-TB.
These authors assumed that male gender could modify the
association between previous treatment and MDR-TB since
men are believed to be less adherent to treatment than
women.26 Interestingly, we found that female gender wasan independent risk factor for MDR-TB in Georgia. Prelimin-
ary results of a population-based study in Georgia also found
that female gender is independently associated with an
increased risk for MDR-TB.31 Our finding in Georgia that
women are at increased risk for MDR-TB if they have TB is
similar to that reported in two studies conducted in former
Soviet republics (Arkhangelsk, Russia, and Estonia).23,32 The
reasons for the association between female gender and MDR-
TB are unclear and deserve further study. We hypothesize
that this association could be related to the fact that women
care for men and others with MDR-TB both in households and
in healthcare settings in Georgia, where the majority of
healthcare workers are female. There has previously been
no treatment available in Georgia for MDR-TB and therefore
such patients likely remain infectious for long periods of
time, increasing the risk of household and institutional trans-
mission of MDR-TB. We found that a higher proportion of
women had new cases of MDR-TB compared to men.
Our study is subject to several limitations. One of these is
the potential misclassification of new and retreatment cases;
some cases registered as new may actually have had TB
treatment in the past. Classification was based on patient
history of prior treatment for TB and review of medical
records (which were not available for all patients enrolled).
Some patients with suspected TB had contaminated cultures
and were excluded from the analysis, which has the potential
for introducing selection bias. In addition, further bias is
possible because our study was carried out at selected sites in
Georgia and was not population-based. The high rate of
missing data among those with a negative AFB culture was
due to the fact that the study focused primarily on patients
with a positive culture. However, our study provides impor-
tant initial data on drug resistance in Georgia and enhanced
infrastructure development, which has allowed for the sub-
sequent development of a population-based study on drug
resistance; this study is ongoing.31
In summary, drug-resistant tuberculosis including MDR-TB
has emerged as a serious public health problem in Georgia
and will greatly impact TB control strategies. The overall
prevalence of MDR-TB was found to be 28.1% (10.5% of newly
diagnosed patients and 53.1% of retreatment cases). In multi-
variate analysis, risk factors for MDR-TB included: being a
retreatment case (PR = 5.28), history of injection drug use
(PR = 1.59), and female gender (PR = 1.36). This study has
important implications for TB control in Georgia. It highlights
the need to fully implement the Georgia National Tubercu-
losis Program’s new five-year plan for TB control, which is
based on The Global Plan to Stop TB (2006—2015).12 This
includes rapid DOTS expansion so that DOTS is fully imple-
mented throughout Georgia in order to prevent further
emergence of drug resistance. Othermeasures include devel-
opment of the capacity to treat those with MDR-TB in Georgia
through implementation of DOTS-Plus (provision of diagnosis,
treatment, and management for all patients with MDR-TB
through the DOTS-Plus strategy), implementation of TB
infection control measures to prevent institutional spread
of tuberculosis, engaging the overall health system in TB-
related activities, empowering patients and communities to
support TB control and reduce TB-related stigma, and
enabling and promoting TB-related research (including
research into simplified and easy to use tests to detect drug
resistance).
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